ClinicalTrials.gg
Status unknownNCT05795829Updated Apr 3, 2023

Ultrasound Ablation for Essential Hypertension(FIM)

An interventional study of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in Uncontrolled Essential Hypertension, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Planned enrollment
65th of 67
10 · median 297
Started
2023
with 6 others
No phase
22 of 76
8 open now
Registered
48th of 76
by date
Lead sponsor
2 of 76
Lepu Medical Technology (Beijing) Co., Ltd.

Among the 76 studies in Essential Hypertension with a site in China, this one is the 65th largest by planned enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2023, is one of 22 with no phase, and was the 48th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and feasibility of disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument in the treatment of essential hypertension.

Read the detailed description

Feasibility Research This is a prospective, small-sample, single-group study. A total of 10 subjects are planned to be included in this study. Disposable intravascular catheter and instrument are used for intravascular ultrasound ablation. All participants will be followed up by telephone or outpatient at 1, 2 and 6 months post-procedure, with procedural success rate as the primary endpoint. At the same time, the incidence of adverse events will be observed to make a preliminary evaluation of the safety and feasibility of disposable intravascular catheter and instrument, and to provide data support for the second-stage confirmatory study.

In feasibility research, statistical analysis of data will be performed after 30 days postoperative follow-up of the subjects, and the safety and feasibility of disposable intravascular catheter and instrument will be preliminarily evaluated before entering the stage of confirmatory trial.

03

Conditions studied

  • Uncontrolled Essential Hypertension

Keywords

  • Ultrasound Ablation Catheter
  • Renal Sympathetic Denervation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 and≤80 years old, no gender limitation;
  2. Two or more antihypertensive drugs should be statically taken for at least 4 weeks before randomization and the prescribed dose should be ≥ 50% of the manufacturer's maximum dose, angiotensin-converting enzyme inhibitor (ACEI) (or angiotensin-Ⅱ receptor antagonist (ARB)) and calcium channel blocker (CCB) (or thiazide diuretic) are required to be used in combination. Blood pressure meets the following conditions: 1) office systolic blood pressure (SBP)≥150mmHg and\<180mmHg; 2) office diastolic blood pressure (DBP) ≥90mmHg;
  3. 24-hour ambulatory systolic blood pressure: ≥135 mmHg and \<170 mmHg;
  4. A recorded history of essential hypertension;
  5. Understands the purpose of this study, and is willing to sign the and complete clinical follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Ineligible renal artery anatomy including : (1) multiple renal arteries, (2) main renal artery diameter \<4mm or length \<20mm, (3) renal artery stenosis > 50% in the main renal artery, (4) atherosclerosis of the renal artery, renal artery aneurysm, fibromuscular dysplasia or calcification, (5) pre-existing renal stent, (6) single kidney
  2. Estimated (eGFR) \<45 mL/min/1.73 m2
  3. Type Ⅰ diabetes mellitus or poorly controlled type Ⅱ diabetes mellitus (defined as plasma Hb1Ac≥ 9.0% or 24-hour urinary protein quantification >1g/24h or proliferative retinopathy)
  4. Postural hypotension
  5. Recent vascular events: Experienced acute myocardial infarction, unstable angina, syncope, or cerebrovascular accident within 3 months of the screening period
  6. Possible secondary hypertension
  7. Respiratory support: The individual requires long-term oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
  8. \<1 year
  9. Female who is pregnant, nursing, or planning to become pregnant
  10. Subjects who are currently enrolled in another clinical trial and have not completed their primary endpoint
  11. Subjects who are allergic to contrast medium
  12. Subjects who are unsuitable for the trial ,because of poor patient compliance or other reasons judged by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Disposable Intravascular Ultrasound Ablation Catheter and Ultrasound Ablation Instrument

    All subjects will receive treatment from the disposable intravascular ultrasound ablation catheter.

    Device: disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument

Interventions

  • Devicedisposable intravascular ultrasound ablation catheter and ultrasound ablation instrument

    Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.

06

What researchers measure

Primary outcomes

  1. Procedural success

    Procedural success was defined as the absence of renal arterial related complication during the subject's hospitalization based on the device success.

    Time frame: Before discharge (post-procedure), up to 7 days

Secondary outcomes

  1. Change in average 24-hour/night-time ambulatory Systolic Blood Pressure (SBP)

    Time frame: 1 month, 2months, 6 months post-procedure

  2. Change in average 24-hour/daytime/night-time ambulatory Diastolic Blood Pressure (DBP)

    Time frame: 1 month, 2months, 6 months post-procedure

  3. Change in average daytime ambulatory Systolic Blood Pressure (SBP)

    Time frame: 1 month, 2months, 6 months post-procedure

  4. Change in office systolic blood pressure

    Time frame: 1 month, 2 months, 6 months post-procedure

  5. Change in office diastolic blood pressure

    Time frame: 1 month, 2 months, 6 months post-procedure

  6. Device success

    Time frame: immediate post-procedure

  7. Incidence of achieving target office systolic blood pressure

    Time frame: 1 month, 2 months, 6 months post-procedure

  8. Significant embolic events resulting in end-organ damage

    Time frame: 1 month, 2 months, 6 months post-procedure

  9. Incidence of acute myocardial infarction, stroke, transient ischemic attack, cerebrovascular accident

    Time frame: 1 month, 2 months, 6 months post-procedure

  10. End-stage renal disease

    Time frame: 1 month, 2 months, 6 months post-procedure

  11. Renal artery or vascular complications requiring intervention

    Time frame: 1 month, 2 months, 6 months post-procedure

  12. Significant (50%) and severe (75%) new onset renal stenosis

    Time frame: 6 months post-procedure

  13. Severe access site complications

    Time frame: 1 month, 2 months, 6 months post-procedure

  14. Incidence of adverse events

    Time frame: 1 month, 2 months, 6 months post-procedure

  15. Stability of ultrasonic ablation instrument

    Whether the instrument has failed during the use of the device, and whether the fault can be recovered.

    Time frame: immediate post-procedure

  16. Interface friendliness of ultrasonic ablation instrument

    It is defined as whether the operation interface and difficulty of operation of the instrument are convenient.

    Time frame: immediate post-procedure

07

Study locations

2 of 2 sites recruiting
  • The Second Affiuated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
    • Jing huang · Contact023-63693083
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, China
    Recruiting
    • Bo Yu · Contact0451-86605180
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2023, 11 months after the start.

Of 80 interventional studies with no phase under Essential Hypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Apr 3, 2023
StartActual
Jan 16, 2023
Primary completionEst.
Dec 31, 2023
CompletionEst.
Feb 29, 2024
Last update
Apr 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05795829
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Jan 16, 2023
Primary completion
Dec 31, 2023 (estimated)
Completion
Feb 29, 2024 (estimated)
Last update
Apr 3, 2023

Study contacts

Ting Zhang
Contact
ting_zhang@lepumedical.com
010-80120666
Bo Yu
study chair · The Second Affiliated Hospital of Harbin Medical University
Jing Huang
study chair · The Second Affiuated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion